Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Armend Lokku

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer|August 8, 2017
Cancer survivorship and opioid prescribing rates: A population-based matched cohort study among individuals with and without a history of cancerRinku Sutradhar, Armend Lokku, Lisa Barbera
American Journal of Perinatology|September 21, 2016
Trends and Outcomes of Patent Ductus Arteriosus Treatment in Very Preterm Infants in CanadaArmend Lokku, Lucia Mirea, Shoo K Lee, et al.
Arthritis Care & Research|January 18, 2023
Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics TrialsLily Siok Hoon Lim, Armend Lokku, Eleanor Pullenayegum, et al.
BMC Medical Research Methodology|May 31, 2020
Summarizing the extent of visit irregularity in longitudinal dataArmend Lokku, Lily S Lim, Catherine S Birken, et al.
The International Journal of Biostatistics|August 15, 2021
Quantifying the extent of visit irregularity in longitudinal dataArmend Lokku, Catherine S Birken, Jonathon L Maguire, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|December 28, 2016
Trends in unintentional injury mortality in Canadian children 1950-2009 and association with selected population-level interventionsSarah A Richmond, Jennifer D'Cruz, Armend Lokku, et al.
Pediatric Rheumatology Online Journal|July 30, 2022
Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trialsLily Siok Hoon Lim, Shamsia Shobhan, Armend Lokku, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled TrialDavid Isenberg, Richard Furie, Nicholas S Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2024
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform NeurofibromaChristopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer|August 8, 2017
Cancer survivorship and opioid prescribing rates: A population-based matched cohort study among individuals with and without a history of cancerRinku Sutradhar, Armend Lokku, Lisa Barbera
American Journal of Perinatology|September 21, 2016
Trends and Outcomes of Patent Ductus Arteriosus Treatment in Very Preterm Infants in CanadaArmend Lokku, Lucia Mirea, Shoo K Lee, et al.
Arthritis Care & Research|January 18, 2023
Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics TrialsLily Siok Hoon Lim, Armend Lokku, Eleanor Pullenayegum, et al.
BMC Medical Research Methodology|May 31, 2020
Summarizing the extent of visit irregularity in longitudinal dataArmend Lokku, Lily S Lim, Catherine S Birken, et al.
The International Journal of Biostatistics|August 15, 2021
Quantifying the extent of visit irregularity in longitudinal dataArmend Lokku, Catherine S Birken, Jonathon L Maguire, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|December 28, 2016
Trends in unintentional injury mortality in Canadian children 1950-2009 and association with selected population-level interventionsSarah A Richmond, Jennifer D'Cruz, Armend Lokku, et al.
Pediatric Rheumatology Online Journal|July 30, 2022
Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trialsLily Siok Hoon Lim, Shamsia Shobhan, Armend Lokku, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled TrialDavid Isenberg, Richard Furie, Nicholas S Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2024
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform NeurofibromaChristopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, et al.
Pageof 1